

REMARKS

Claims 3-9, 14, 63 and 66-68 are pending in the Instant Application. Responsive to the Examiner's requirement and Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants submit herewith a substitute and revised Sequence Listing along with a substitute Computer Readable Form.

Applicants have above amended the Claims, specifically Claims 5, 6, 7 and 9, to appropriately and correctly refer to SEQ ID NOs and particularly in order that any sequence that is made up of one or more noncontiguous segments of a larger sequence or segments from different sequences is present as a separate sequence. The above amendments and revised Sequence Listing provide no new matter and are merely references to specific and appropriate SEQ IDs in order that the claimed polypeptides are clear and refer to separate sequences as appropriate.

Applicants submit concurrently herewith a substitute computer readable form (CRF) and paper copy of the Sequence Listing, as well as a Statement in Support of the Filing/Submission of a Nucleotide/Amino Acid Sequence Listing. Applicants respectfully request and direct entry of the attached paper copy of the Sequence Listing in the Specification.


No fees are believed to be necessitated by the foregoing amendments. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

PATENT
600-1-162

Early and favorable action on the merits of the Claims is earnestly solicited.

Respectfully submitted,

KLAUBER & JACKSON

A handwritten signature in black ink, appearing to read "Christine E. Dietzel", is written over a horizontal line.

Christine E. Dietzel, Ph.D.
Agent for Applicant(s)
Registration No. 37,309

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack NJ 07601
Tel: (201) 487-5800

Date: March 11, 2003

VERSION WITH MARKINGS TO SHOW CHANGES MADE

5. A leptin receptor (OB-R) polypeptide which is selected from the group consisting of OB-Ra (SEQ ID NO:2), OB-Rb (SEQ ID NO:4), OB-Rc (SEQ ID NO:6), OB-Rd (SEQ ID NO:8), and OB-Re (SEQ ID NO:10), or allelic variants thereof.
6. A leptin receptor (OB-R) polypeptide which is selected from the group consisting of:
- a) N-terminal corresponding to OB-Ra through Lys⁸⁸⁹ and C-terminal to a C-terminal selected from the group consisting of OB-Rb after Lys⁸⁸⁹ (SEQ ID NO:57), OB-Rc after Lys⁸⁸⁹ (SEQ ID NO:58), and OB-Rd after Lys⁸⁸⁹ (SEQ ID NO:59);
 - b) N-terminal corresponding to OB-Rb or OB-Rc through Lys⁸⁸⁹, and C-terminal corresponding to OB-Ra after Lys⁸⁸⁹ (SEQ ID NO:60,61) or OB-Rd after Lys⁸⁸⁹ (SEQ ID NO:62,63);
 - c) N-terminal corresponding to OB-Rd through Lys⁸⁸⁹, and C-terminal corresponding to OB-Ra after Lys⁸⁸⁹ (SEQ ID NO:64), OB-Rb after Lys⁸⁸⁹ (SEQ ID NO:65), or OB-Rc after Lys⁸⁸⁹ (SEQ ID NO:66);
 - d) N-terminal corresponding to SEQ ID NO:55 from Pro⁶⁶⁴ to Lys⁸⁸⁹, and C-terminal corresponding to OB-Ra after Lys⁸⁸⁹ (SEQ ID NO:67), OB-Rb after Lys⁸⁸⁹ (SEQ ID NO:68), OB-Rc after Lys⁸⁸⁹ (SEQ ID NO:69), or OB-Rd after [from] Lys⁸⁸⁹ (SEQ ID NO:70);
 - e) N-terminal corresponding to SEQ ID NO:55 from Met⁷³³ to Lys⁸⁸⁹, and C-terminal corresponding to OB-Ra after Lys⁸⁸⁹ (SEQ ID NO:71), OB-Rb after Lys⁸⁸⁹ (SEQ ID NO:72), OB-Rc after Lys⁸⁸⁹ (SEQ ID NO:73), or OB-Rd after [from] Lys⁸⁸⁹ (SEQ ID NO:74);
 - f) N-terminal selected from the group consisting of OB-Ra, OB-Rb, OB-Rd, and OB-R from Pro⁶⁶⁴ to His⁷⁹⁶, and OB-Re from His⁷⁹⁶ (SEQ ID NO:75, 76, 77, and 78);
 - g) N-terminal corresponding to SEQ ID NO:55 from Met⁷³³ to His⁷⁹⁶, and OB-Re from His⁷⁹⁶ (SEQ ID NO:79); and

- h) allelic variants of any of subparts a) through g).

7. A leptin receptor (OB-R) polypeptide wherein

- a) the N-terminal sequence is selected from the group consisting of
- xi. amino acid residues 1-889 (SEQ ID NO:80);
 - xii. amino acid residues 23-889 (SEQ ID NO:81);
 - xiii. amino acid residues 28-889 (SEQ ID NO:82);
 - xiv. amino acid residues 133-889 (SEQ ID NO:83);
 - xv. amino acid residues 733-889 (SEQ ID NO:84);
 - xvi. amino acid residues 1-796 (SEQ ID NO:85);
 - xvii. amino acid residues 23-796 (SEQ ID NO:86);
 - xviii. amino acid residues 28-796 (SEQ ID NO:87);
 - xix. amino acid residues 133-796 (SEQ ID NO:88);
 - xx. amino acid residues 733-796 (SEQ ID NO:89); and
- xi) allelic variants of any of subparts i) through x); and
- b) the C-terminal sequence is selected from the group consisting of
- i) SEQ ID NO:11;
 - ii) SEQ ID NO:12;
 - iii) SEQ ID NO:13;
 - iv) SEQ ID NO:14;
 - v) SEQ ID NO:15 after His⁷⁹⁶ (SEQ ID NO:90); and
 - vi) allelic variants of any of subparts i) through v);

wherein the numbering in subpart a) is based on the amino acid sequence of SEQ ID NO:55

9. The soluble leptin receptor of Claim 8 which is selected from the group consisting of

- a) OB-Re (SEQ ID NO:10);
- b) an N-terminal sequence which is selected from the group consisting of:
- i) OB-Ra (SEQ ID NO:2),

- ii) OB-Rb (SEQ ID NO:4),
 - iii) OB-Rd (SEQ ID NO:8), and
 - iv) corresponding to SEQ ID NO:55 from Pro⁶⁶⁴, through His⁷⁹⁶ [His⁷⁹⁹],
- and a C-terminal sequence which is OB-Re from His⁷⁹⁶ (SEQ ID NO:91); and
- v) allelic variants of any of subparts i) through iv);
- c) an N-terminal sequence which is selected from the group consisting of
- i) amino acid residues 1-796 (SEQ ID NO:85);
 - ii) amino acid residues 23-796 (SEQ ID NO:86);
 - iii) amino acid residues 28-796 (SEQ ID NO:87);
 - iv) amino acid residues 133-796 (SEQ ID NO:88);
 - v) amino acid residues 733-796 (SEQ ID NO:89); and
 - vi) allelic variants of any of subparts i) through v); and
- a C-terminal sequence which is SEQ ID NO:15;
- wherein the numbering in subparts b) and c) is based on the amino acid sequence of SEQ ID NO:55.